TW202317084A - 新穎治療 - Google Patents

新穎治療 Download PDF

Info

Publication number
TW202317084A
TW202317084A TW111125748A TW111125748A TW202317084A TW 202317084 A TW202317084 A TW 202317084A TW 111125748 A TW111125748 A TW 111125748A TW 111125748 A TW111125748 A TW 111125748A TW 202317084 A TW202317084 A TW 202317084A
Authority
TW
Taiwan
Prior art keywords
stem cell
patient
multiple myeloma
refractory
salt
Prior art date
Application number
TW111125748A
Other languages
English (en)
Chinese (zh)
Inventor
賈克伯 林德柏格
Original Assignee
瑞典商腫瘤多肽股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2109894.2A external-priority patent/GB202109894D0/en
Priority claimed from GBGB2112976.2A external-priority patent/GB202112976D0/en
Application filed by 瑞典商腫瘤多肽股份公司 filed Critical 瑞典商腫瘤多肽股份公司
Publication of TW202317084A publication Critical patent/TW202317084A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111125748A 2021-07-08 2022-07-08 新穎治療 TW202317084A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB2109894.2 2021-07-08
GBGB2109894.2A GB202109894D0 (en) 2021-07-08 2021-07-08 Novel treatments
GB2112976.2 2021-09-10
GBGB2112976.2A GB202112976D0 (en) 2021-09-10 2021-09-10 Novel treatments

Publications (1)

Publication Number Publication Date
TW202317084A true TW202317084A (zh) 2023-05-01

Family

ID=82702963

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111125748A TW202317084A (zh) 2021-07-08 2022-07-08 新穎治療

Country Status (5)

Country Link
US (1) US20240307480A1 (cg-RX-API-DMAC7.html)
EP (1) EP4366721A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024524552A (cg-RX-API-DMAC7.html)
TW (1) TW202317084A (cg-RX-API-DMAC7.html)
WO (1) WO2023281007A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121349A1 (en) * 2022-12-08 2024-06-13 Oncopeptides Ab Therapeutic treatment for haematological cancer based on the level of t-cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
SI3228319T1 (sl) 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
WO2020079165A1 (en) 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Also Published As

Publication number Publication date
EP4366721A1 (en) 2024-05-15
JP2024524552A (ja) 2024-07-05
WO2023281007A1 (en) 2023-01-12
US20240307480A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP6759402B2 (ja) Flt3変異を有する急性骨髄性白血病の治療用の医薬組成物
JP7445893B2 (ja) ヒトにおける固形腫瘍の処置のためのC.novyi
EP3383385B2 (en) Melflufen dosage regimens for cancer
EP4322942A1 (en) Combination comprising everolimus and amcenestrant
US11241448B2 (en) Methods for cancer therapy
JP2024516363A (ja) リボシクリブ及びアムセネストラントを含む組み合わせ
JP2019515889A (ja) (1s,4s)−4−(2−(((3s,4r)−3−フルオロテトラヒドロ−2h−ピラン−4−イル)アミノ)−8−((2,4,6−トリクロロフェニル)アミノ)−9h−プリン−9−イル)−1−メチルクロロヘキサン−1−カルボキサミドの固体形態及びその使用方法
US20260053791A1 (en) Use of tivozanib to treat subjects with refractory cancer
US20240307480A1 (en) Melflufen for use in the treatment of multiple myeloma
WO2021140478A1 (en) Combination therapy for treating cancer
TWI776451B (zh) Bcl-2/bcl-xl抑制劑之組合及相關用途
EP4054582A1 (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
CN117940119A (zh) 美氟芬用于多发性骨髓瘤的治疗
González-Vílchez et al. Conversion from immediate-release tacrolimus to prolonged-release tacrolimus in stable heart transplant patients: a retrospective study
JP2019529562A (ja) 血液癌治療のためのhdac阻害剤およびプロテアソーム抑制剤または免疫調節性薬物を含む薬学的調合物
AU2012237751A1 (en) Ezatiostat for treating multiple myeloma
US20240207281A1 (en) Methods of treating b-cell lymphoma using combination therapy
US20220193019A1 (en) Treatment of al amyloidosis with melflufen
Agarwala Evolving Considerations in the Treatment and Management of Metastatic Melanoma: Expert Strategies on Immune Checkpoint Inhibitors.
TW202510860A (zh) 使用氮雜雙環式化合物與抗雄性激素劑之癌症併用療法
HK1260696B (en) Melflufen dosage regimens for cancer
HK1260696A1 (en) Melflufen dosage regimens for cancer